

January 29, 2018



Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th

BOSTON, MA -- (Marketwired) -- 01/29/18 -- **Pieris Pharmaceuticals, Inc.** (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin[®] technology platform for cancer, respiratory and other diseases, announced today that it will host a Key Opinion Leader (KOL) Event in New York on Tuesday, February 6th from 8-10:30 AM EDT.

The KOL event will feature world-class thought leaders in immuno-oncology and respiratory diseases, followed by a company presentation. The event will include presentations from:

- **Michael A. Curran**, PhD, Assistant Professor in the Department of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson Cancer Center.
- **David H. Ilson**, MD PhD, Medical Oncologist and Attending Physician at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College.
- **Gary Anderson**, PhD, FThorSoc, FERS, Professor in the Medical Faculty at the University of Melbourne and Director of the Centre for Lung Health Research.
- **Bruce Levy**, MD, Parker B. Francis Professor of Medicine at Brigham and Women's Hospital and the Chief of the Pulmonary and Critical Care Division.

The event will be accessible via a live webcast through this [link](#) beginning at 8am on February 6th.

In-person attendance is by invitation only. For more information please contact Clayton Robertson at crobertson@troutgroup.com.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin[®] is a registered trademark of Pieris. For more information, visit www.pieris.com.

Contacts at Pieris:

Company Contact:

Pieris Pharmaceuticals, Inc.

Allan Reine

SVP & Chief Financial Officer

+1-857-444-4276

reine@pieris.com

Investor Relations Contact:

The Trout Group

Thomas Hoffmann

+1-646-378-2931

thoffmann@troutgroup.com

Source: Pieris Pharmaceuticals, Inc.